<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="471744,51799">Imipenem</z:chebi>/cilastatin <z:chebi fb="199" ids="26708">sodium</z:chebi> (<z:chebi fb="54" ids="17202">IMP</z:chebi>/CS) was administered to patients with severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> complicated by <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> to assess its efficacy and safety </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">Primary diseases</z:e> in this series of 76 cases included 37 cases of <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> (<z:hpo ids='HP_0002488'>acute leukemia</z:hpo> in 25 cases, malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in 7 cases, <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in 3 cases and 2 other diseases) and 38 cases of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (<z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> in 7 cases, <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> in 11 cases, <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> in 6 cases, <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> in 3 cases, <z:e sem="disease" ids="C0740277" disease_type="Neoplastic Process" abbrv="">bile duct cancer</z:e> in 4 cases, hepatocellular <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in 3 cases, and 4 other diseases) </plain></SENT>
<SENT sid="2" pm="."><plain>Following results were obtained </plain></SENT>
<SENT sid="3" pm="."><plain>1 </plain></SENT>
<SENT sid="4" pm="."><plain>Types of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> were <z:hpo ids='HP_0100806'>sepsis</z:hpo> in 5 cases, suspected <z:hpo ids='HP_0100806'>sepsis</z:hpo> in 24 cases, <z:hpo ids='HP_0002090'>pneumonia</z:hpo> in 5 cases and 3 others </plain></SENT>
<SENT sid="5" pm="."><plain>The efficacy rates were 100% in <z:hpo ids='HP_0100806'>sepsis</z:hpo>, 62.5% in suspected <z:hpo ids='HP_0100806'>sepsis</z:hpo>, 80% in <z:hpo ids='HP_0002090'>pneumonia</z:hpo> and 73% in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="6" pm="."><plain>2 </plain></SENT>
<SENT sid="7" pm="."><plain>Types of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> were <z:hpo ids='HP_0100806'>sepsis</z:hpo> in 2 cases, suspected <z:hpo ids='HP_0100806'>sepsis</z:hpo> in 13 cases, <z:hpo ids='HP_0002090'>pneumonia</z:hpo> in 10 cases, <z:hpo ids='HP_0001082'>cholecystitis</z:hpo> in 2 cases, <z:mp ids='MP_0003254'>cholangitis</z:mp> in 5 cases, <z:hpo ids='HP_0100523'>liver abscess</z:hpo> in 2 cases, and 4 others </plain></SENT>
<SENT sid="8" pm="."><plain>The efficacy rates were 50% in <z:hpo ids='HP_0100806'>sepsis</z:hpo>, 69.2% in suspected <z:hpo ids='HP_0100806'>sepsis</z:hpo>, 80% in <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, and 71.1% in <z:hpo ids='HP_0000001'>all</z:hpo> cases </plain></SENT>
<SENT sid="9" pm="."><plain>3 </plain></SENT>
<SENT sid="10" pm="."><plain>IPM/CS was administered in single use in 66 cases and in combination with other antibiotics in 9 cases </plain></SENT>
<SENT sid="11" pm="."><plain>The efficacy rate in the single use was 72.7% and that in the combination use was 66.7% </plain></SENT>
<SENT sid="12" pm="."><plain>4 </plain></SENT>
<SENT sid="13" pm="."><plain>The efficacy rate in 35 cases of first use was 71.4% and that in 40 cases of second use was 72.5%.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>